Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Oncology APIs. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel alkaline salt-assisted cyclization improves Bosutinib yield and purity. Ideal for reliable API supplier partnerships seeking cost reduction.
Patent CN101585745B details a high-yield synthesis of key oncology intermediates. Discover cost-effective manufacturing solutions for tetrahydroisoquinoline alkaloids.
Advanced patent analysis of CN86104664A reveals novel dehydrogenation routes for high-purity steroid intermediates, offering significant cost reduction in API manufacturing and enhanced supply chain reliability.
Explore novel macrocyclic TRK/ALK inhibitors from CN111171049A. Discover scalable synthesis routes for drug-resistant cancer intermediates and supply chain advantages.
Advanced synthetic route for epirubicin hydrochloride via chiral reduction. Offers high purity, reduced costs, and scalable manufacturing for global pharmaceutical supply chains.
Patent CN111471077B reveals a novel 2-deoxy-D-ribose derivative route achieving 8:1 beta-selectivity. Discover cost-effective, scalable manufacturing for oncology APIs.
Advanced synthesis of bendamustine intermediate via reductive alkylation. Superior purity >99.5% and optimized yield for reliable pharmaceutical supply chains.
Patent CN102702178B details a novel Lapatinib synthesis using THP protection for improved solubility and cost reduction in API manufacturing supply chains.
Patent CN111349081B reveals a chiral protonic acid catalyzed Ugi reaction for Ivosidenib, eliminating chiral columns and toxic solvents for scalable manufacturing.
Patent CN110944974B details a novel oleum-based nitration process for 5-fluoro-2-methyl-3-nitrobenzoic acid, offering superior yield and purity for PARP inhibitor manufacturing.
Patent CN111620860B reveals a streamlined synthesis for Afuresertib, eliminating complex protection steps for significant cost reduction and supply chain reliability in AKT inhibitor manufacturing.
Advanced low-cost synthesis route for EGFR inhibitor intermediates like Gefitinib and Erlotinib via optimized nitration and cyclization strategies.
Advanced semi-synthetic route for Paclitaxel using CeCl3 catalysis. High-yield process suitable for industrial scale-up and cost-effective API manufacturing.
Patent CN109678853B reveals a green one-pot dasatinib synthesis using ionic liquids, offering high purity and cost reduction for pharmaceutical manufacturing supply chains.
Patent CN112142804B reveals a novel decitabine preparation method using supercritical fluid separation, offering high purity and reduced solvent consumption for pharmaceutical manufacturing.
Advanced synthesis of Pemetrexed disodium intermediate via amino protection strategy. Reduces impurities, lowers costs, and ensures reliable supply for oncology drug manufacturing.
Patent CN103298795A details a novel oxalate salt crystallization process for Letrozole intermediates, eliminating regioisomers and enabling scalable API manufacturing.
Novel preparation method for Ibrutinib intermediates avoiding Mitsunobu reaction. High yield, low cost, and scalable process for pharmaceutical manufacturing.
Patent CN114044777A reveals a cost-effective route for Ruxolitinib Phosphate using Nickel catalysis and chiral resolution, offering high purity and scalable manufacturing for global supply chains.
Patent CN101469008A reveals a novel orthoester protection strategy for Capecitabine synthesis, enabling mild hydrolysis, superior purity, and cost-effective commercial manufacturing.